Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Worth $3.4 Billion By 2025: Grand View Research, Inc.

Wednesday, October 18, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, October 18, 2017 /PRNewswire/ --

The global acute lymphocytic/lymphoblastic leukemia therapeutics market

is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number
of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

(Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Browse full research report with TOC on "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis By Therapy (Chemotherapy, Hyper-CVAD, Linker Regimen, Targeted Therapy, Radiation Therapy), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market

Further Key Findings From the Report Suggest:

  • Chemotherapy dominated the market in 2016 owing to its high prescription rate, presence of a wide product portfolio, and easy availability of products
  • Targeted therapy is anticipated to be the most preferred therapy in comparison to other types of therapies due to its associated benefits such as target-specific action and its ability to prevent collateral damage, leading to faster recovery
  • Precursor B-ALL dominated the market in 2016 and is expected to be the fastest growing segment during the forecast period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are its subtypes
  • North America dominated the market in 2016 owing to factors such as the increase in demand for chemotherapy regimen such as CALGB 8811 and oncaspar in this region
  • Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to growing awareness about ALL. Furthermore, the rising disposable income and presence of large population base are some of the factors expected to propel the growth in this region
  • Key players in this industry are Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme Corporation
  • Key players are focusing on strategies such as expansion of product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use Next-Generation Sequencing (NGS) technology to develop gene expression profiles for immune-oncology therapies

Browse related reports by Grand View Research:

  • Genetic Disease Diagnostic Market - http://www.grandviewresearch.com/industry-analysis/genetic-disease-diagnostic-market
  • Biotechnology Reagents Market - http://www.grandviewresearch.com/industry-analysis/biotechnology-reagent-market
  • Artemisinin Market - http://www.grandviewresearch.com/industry-analysis/artemisinin-market
  • Kidney Cancer Drugs Market - http://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market

Grand View Research has segmented the global acute Lymphocytic/Lymphoblastic leukemia therapeutics market on the basis of therapy, type, and region:

  • Therapy Outlook (Revenue, USD Million; 2014 - 2025)
    • Chemotherapy
      • Hyper-CVAD
      • CALGB 8811 regimen
      • Linker regimen
      • Nucleoside Metabolic Inhibitors
      • Oncaspar
    • Targeted therapy
    • Radiation Therapy
    • Stem cell transplantation
  • Type Outlook (Revenue, USD Million; 2014 - 2025)
    • Philadelphia chromosome
    • Precursor B-cell ALL
    • T-cell ALL
  • Regional Outlook (Revenue, USD Million; 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
      • France
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Read Our Blog By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. Thecompany provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected]

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store